USPTO serial 78214938
BIOWAMED
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- RAUEN, JAMES
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with BIOWAMED?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Lawrence E. Abelman
LAWRENCE E ABELMAN ABELMAN FRAYNE & SCHWAB666 3RD AVE 10TH FLNEW YORK, NY 10017UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biochemicals, namely, monoclonal antibodies, fragments of such antibodies and derivatives of such antibodies for in vitro scientific or research use; cells for scientific, laboratory or medical research cells that manufacture antibody, fragment of antibody or derivatives of antibody; cells for scientific, laboratory or medical research, namely, transfected cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies; host cells for scientific, laboratory or medical research | ACTIVE | — |
| 005 | Cells for medical or clinical use that manufacture antibodies, fragments of antibodies or derivatives of antibodies; cells for medical or clinical use, namely, transfected cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies; host cells for medical or clinical use; pharmaceuticals, namely, central nervous system depressants, preparations for ophthalmic use, anti-histaminics, cardiotonics, arrhythmia treating agents, diuretics, hypotensors, prophylactic for the treatment of asthma, antitussives and expectorants, stomachics and digestives, antacids, hormones, namely, pituitary hormones for the treatment of infertility, thyroid hormones for the treatment of hyperthyroidism, anabolic hormones for the treatment of aplastic anemia and osteoporosis, corticosteroids for treatment of hypopituitarism, congenital adrenal hyperplasia, rheumatoid arthritis, rheumatic fever, crohn's disease, and chronic active hepatitis, estrogen and progesterone used as combined oral contraceptives, urinary antiseptics, analgesics, anti-itching agents, cataplasms for the treatment of bruises, lumbago and stiff shoulder, pharmaceutical preparations used to treat hair disorders, vitamin preparations, food enriching agents for treating vitamin deficiencies, anti-coagulants, enzyme preparations for control of malabsorption and diarrhea, anti-cancer preparations, anti-sarcoma preparations, antibiotics and their preparations for the treatment of infectious diseases, antituberculotic agents, influenza vaccines, diphtheria vaccines, tetanus vaccines, gas gangrene vaccines, Japanese encephalitis vaccines, in vitro tetrodotoxines for medical use, antiprotozoals for the treatment of trichomoniasis and dermatophytosis, anthelmintics for the treatment of threadworm and toxoplasmaosis, naturally occurring drugs for treating peptic ulcers, charred drugs for treating peptic ulcers, moxa for treating peptic ulcers, veterinary drugs for the treatment of distemper in dogs, distomatosis in dogs, coccidium in chickens, and dysentery in pigs, germination controllers and plant rearing agents, namely, herbicides, fungicides, insecticides, bactericides and rodenticides for domestic and/or agricultural use, antiseptics, drugs for arteriosclerosis, oncostatic drugs for the treatment for cancer, multienzyme digestants for in vivo use, antifungal antibiotics for treating trichomoniasis and dermatophytosis, antiparkinsonism drugs, minor tranquilizers, and antianxiety agents, medicinal preparations for the treatment of the central nervous system, the respiratory tract and the cardiovascular system, vitamins, anti-bacterial preparations, mucolytic preparations, medicinal preparations for the treatment of peptic ulcers, anti-inflammatory preparations, analgesic preparations, cephalosporin, cocarboxylase preparations, glutathione preparations, preparations for improving the metabolism and the peripheral circulation, plasma substitutes and extracorporeal circulation flow improvement preparations, diuretic and anti-hypertensive preparations, in vitro diagnostic reagents for medical use, in vitro extracorporeal diagnostic reagents for medical use, in vitro X-ray contrast agents for medical use, in vitro diagnostic media, pharmaceutical preparations for the treatment of insomnia and other sleep related diseases | ACTIVE | — |
| 040 | Custom manufacturing of antibodies, fragments of such antibodies and derivatives of such antibodies; custom manufacturing of cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies; custom manufacturing of transfected cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies; custom manufacturing of host cells | ACTIVE | — |
| 042 | Contract development of antibodies, fragments of such antibodies and derivatives of such antibodies; contract development of cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies; contract development of transfected cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies; contract development of host cells | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Kyowa Hakko Kogyo Co., Ltd.
- Other trademarks owned by Kyowa Hakko Kogyo Co., Ltd.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 040
- Other trademarks in Class 042
- Similar marks named BIOWAMED
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 16, 2006 | MAB6 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| May 16, 2006 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Apr 7, 2006 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Feb 7, 2006 | PAPER RECEIVED | — | |
| Sep 7, 2005 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Sep 7, 2005 | EXT2 | SOU EXTENSION 2 FILED | — |
| Sep 7, 2005 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 19, 2005 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Mar 10, 2005 | EXT1 | SOU EXTENSION 1 FILED | — |
| Mar 10, 2005 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 14, 2004 | NOAM | NOA MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jun 22, 2004 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 2, 2004 | NPUB | NOTICE OF PUBLICATION | — |
| Apr 14, 2004 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 17, 2004 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 3, 2004 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 2, 2004 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 2, 2004 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 9, 2004 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 9, 2004 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 12, 2003 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 11, 2003 | DOCK | ASSIGNED TO EXAMINER | — |